# ClinicalTrials.gov record NCT03439943

> PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct03439943-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03439943-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03439943-lixisenatide-v1.json
- Content SHA-256: `901a7a15b770d52d236746574ba1c14e0936bd7aa07ad960180ac4832d808526`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03439943 ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`](#source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa))

## Sources

<a id="source-ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa"></a>
- **ClinicalTrials.gov record NCT03439943 · retained source version 2025-11-28:e2cdd6e285aac13a00f38a3d2f833c86f7158b70b2914cf3851a8dc62cf24ad1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03439943) (`ctg-observation-nct03439943-2025-11-28-e2cdd6e285aa`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03439943." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03439943-lixisenatide-v1.json SHA-256: 901a7a15b770d52d236746574ba1c14e0936bd7aa07ad960180ac4832d808526.